Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA-3 TriaL (VITAL)
| Autor: | Nancy R. Cook, Meryl S. LeBoff, I-Min Lee, Julie E. Buring, Catherine M. Donlon, JoAnn E. Manson, Gregory Kotler, Vadim Bubes, Samia Mora, Sharon H. Chou, Elle M Murata |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Vitamin musculoskeletal diseases Adult Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Population Osteoporosis 030209 endocrinology & metabolism Gastroenterology Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Absorptiometry Photon Bone Density Internal medicine Fatty Acids Omega-3 Outcome Assessment Health Care medicine Vitamin D and neurology Humans Orthopedics and Sports Medicine Quantitative computed tomography Vitamin D education Femoral neck Netherlands Bone mineral education.field_of_study medicine.diagnostic_test business.industry Femur Neck medicine.disease Vitamin D and Omega-3 Trial Fibroblast Growth Factor-23 030104 developmental biology medicine.anatomical_structure chemistry Dietary Supplements Female business |
| Zdroj: | J Bone Miner Res |
| Popis: | Although supplemental vitamin D is used to promote bone health in the general population, data from randomized controlled trials (RCTs) have been inconsistent. We determined whether daily, vitamin D3 supplementation improves bone mineral density (BMD) and/or structure. VITamin D and OmegA-3 TriaL (VITAL) is a double-blind, placebo-controlled RCT of supplemental vitamin D3 (2000 IU/d) and/or omega-3 fatty acids (1 g/d) in 25,871 adults nationwide. This ancillary study included a subcohort of 771 participants (men ≥50 and women ≥55 years; not taking bone active medications) evaluated at baseline and at 2-year follow-up (89% retention). Total 25(OH)D levels were measured by liquid chromatography tandem mass spectrometry (Quest Diagnostics, San Juan Capistrano, CA, USA). Free 25(OH)D (FVD) levels were measured using the ELISA assay by Future Diagnostics Solutions BV (Wijchen, Netherlands). Primary endpoints were 2-year changes in areal (a) BMD at the spine, hip, and whole body determined by dual-energy X-ray absorptiometry (DXA). Secondary endpoints were 2-year changes in volumetric (v) BMD and cortical thickness at the radius and tibia assessed by peripheral quantitative computed tomography. Supplemental vitamin D3 versus placebo had no effect on 2-year changes in aBMD at the spine (0.33% versus 0.17%; p = 0.55), femoral neck (-0.27% versus -0.68%; p = 0.16), total hip (-0.76% versus -0.95%; p = 0.23), or whole body (-0.22% versus -0.15%; p = 0.60), or on measures of bone structure. Effects did not vary by sex, race/ethnicity, body mass index, or 25(OH)D levels. Among participants with baseline FVD levels below the median ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|